Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Daratumumab is approved by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of multiple myeloma and marketed under the brand name Darzalex®.

It’s one of the few cancers still considered incurable, and those diagnosed with multiple myeloma will likely die from the ...

Daratumumab-VRd’s overall safety profile ... created and published by Pharmaceutical Technology, a GlobalData owned brand.

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

Daratumumab-VRd’s overall safety profile ... created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for ...

The FDA's new Breakthrough Therapy designation may offer oncology brands a powerful way forward ... stock rose 10% on the announcement that its daratumumab had been approved as well.

“Preliminary results are encouraging, with 100 percent of patients achieving the primary endpoint of successful CD34+ stem cell mobilization, including patients previously treated with ...

This novel predictor is designed to identify multiple myeloma patients most likely to benefit from daratumumab. The daratumumab DRP ® was developed by correlating gene expression patterns with ...